Ramucirumab
Records for this ingredient, by country (identity only).
ATC L01FG02 · 12 markets · 24 records
GB 4 records · 2 shown of 2
- 500 mg/50 mLinjectionCyramza 500mg/50ml concentrate for solution for infusion vials
- 100 mg/10 mLinjectionCyramza 500mg/50ml concentrate for solution for infusion vials
ES 4 records · 1 shown of 1
- 10 mg/1 mLinjectionCYRAMZA
US 2 records · 1 shown of 1
- 10 mg per mL / per unit basis not statedliquidCYRAMZA
SG 2 records · 1 shown of 1
- 10 mg/mL per mL / per unit basis not statedinjectionCYRAMZA CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/10ML
JP 2 records · 2 shown of 2
- 500 mg/50 mLinjectionサイラムザ点滴静注液500mg
- 100 mg/10 mLinjectionサイラムザ点滴静注液500mg
CA 1 records · 1 shown of 1
- 10 mg per mL / per unit basis not statedliquidCYRAMZA
TW 1 records · 0 shown of 0
1 records · 0 manufacturers 1 registros · 0 fabricantes 1 个记录 · 0 个厂家 1 個記錄 · 0 個廠商
Full list in the data package Lista completa en el paquete de datos 完整清单见数据包 完整清單見資料包
HK 1 records · 0 shown of 0
1 records · 0 manufacturers 1 registros · 0 fabricantes 1 个记录 · 0 个厂家 1 個記錄 · 0 個廠商
Full list in the data package Lista completa en el paquete de datos 完整清单见数据包 完整清單見資料包
EU 1 records · 0 shown of 0
EU centralised authorisation (EMA) — Authorised at EU level — not a record of sale in any single country. The EU register carries no strength, dosage form or pack size.
1 records · 0 manufacturers 1 registros · 0 fabricantes 1 个记录 · 0 个厂家 1 個記錄 · 0 個廠商
Full list in the data package Lista completa en el paquete de datos 完整清单见数据包 完整清單見資料包
FR 1 records · 1 shown of 1
- 10 mg/1 mLinjectionCYRAMZA 10 mg/ml, solution à diluer pour perfusion
Some strengths are recorded without a per mL / per unit basis. They are shown as recorded and are not compared with other markets.
| Strength / form / release | US | GB | CA | SG | CN | ES | TW | HK | JP | EU | FR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 500 mg/50 mL injection | Cyramza 500mg/50ml concentrate for solution for infusion vials | 希冉择雷莫西尤单抗 | サイラムザ点滴静注液500mg | ||||||||
| 100 mg/10 mL injection | Cyramza 500mg/50ml concentrate for solution for infusion vials | 希冉择雷莫西尤单抗 | サイラムザ点滴静注液500mg | ||||||||
| 10 mg per mL / per unit basis not stated cannot compare liquid | CYRAMZA | CYRAMZA | |||||||||
| 10 mg/1 mL injection | CYRAMZA | CYRAMZA 10 mg/ml, solution à diluer pour perfusion | |||||||||
| 10 mg/mL per mL / per unit basis not stated cannot compare injection | CYRAMZA CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/10ML | ||||||||||
injection | CYRAMZA 欣銳擇 注射劑 | ||||||||||
unknown | CYRAMZA CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/10ML | CYRAMZA |
Scroll horizontally for more markets →
Each country column shows the locally registered trade names — not translations.
4 more strength/form rows are recorded only in SG · ES · TW · HK · EU · FR and are not shown in this table. Hay 4 filas de concentración/forma registradas solo en SG · ES · TW · HK · EU · FR que no se muestran en esta tabla. 另有 4 个规格/剂型仅在 SG · ES · TW · HK · EU · FR 有记录（未在本表显示）。 另有 4 個規格/劑型僅在 SG · ES · TW · HK · EU · FR 有記錄（未在本表顯示）。
“not disclosed” means the source does not publish the strength — it does not mean the product has none.
Hong Kong records are name/ingredient-level only: no strength, dosage form or registration status; on the register does not prove current supply.
EU centralised authorisation (EMA) — Authorised at EU level — not a record of sale in any single country. The EU register carries no strength, dosage form or pack size.
Discontinued, withdrawn or unverified-status products are hidden by default; Hong Kong and Australia records are shown as exceptions.